## University of Texas at El Paso

From the SelectedWorks of Laura Elena O'Dell

2009

# Nicotine withdrawal produces fewer decreases in extracellular levels of dopamine in the nucleus accumbens of adolescent versus adult rats.

Laura O'Dell, University of Texas at El Paso



Available at: https://works.bepress.com/laura\_odell/2/

#### Synapse Journal

Copy of e-mail Notification

Synapse Published by Wiley-Liss

Dear Author,

Your page proofs are available in PDF format; please refer to this URL address http://kwglobal.co.in/jw/retrieval.aspx?pwd=04557323b851

Login: your e-mail address Password: 04557323b851

The site contains 1 file. You will need to have Adobe Acrobat Reader software to read these files. This is free software and is available for user downloading at http://www.adobe.com/products/acrobat/readstep.html. If you have the Notes annotation tool (not contained within Acrobat reader), you can make corrections electronically and return them to Wiley as an e-mail attachment (see the Notes tool instruction sheet). Alternatively, if you would prefer to receive a paper proof by regular mail, please contact Sankar/Prashant/Balaji (e-mail: wileysupport@kwglobal.com, phone: ++91 44 42058888, extn.: 310). Be sure to include your article number.

This file contains:

Author Instructions Checklist Adobe Acrobat Users - NOTES tool sheet Reprint Order form Copyright Transfer Agreement Return fax form A copy of your page proofs for your article

After printing the PDF file, please read the page proofs carefully and:

- 1) indicate changes or corrections in the margin of the page proofs;
- 2) answer all queries (footnotes A,B,C, etc.) on the last page of the PDF proof;
- 3) proofread any tables and equations carefully;
- 4) check that any Greek, especially "mu", has translated correctly.

Special Notes:

Within 48 hours, please fax or e-mail the following to the address given below:

- 1) original PDF set of page proofs,
- 2) print quality hard copy figures for corrections and/or TIFF or EPS files of figures for correction (if necessary),
- 3) Signed Copyright Transfer Agreement,

#### Synapse Journal

Copy of e-mail Notification

4) Reprint Order form,

5) Return fax form

Return to:

Production Editor, SYN DPS Ephrata 300 West Chestnut Street Ephrata, PA 17522

(See fax number and e-mail address below.)

If you experience technical problems, please contact Prasanth/Sankar/Balaji(e-mail: wileysupport@kwglobal.com, phone: +91 (44) 4205-8888 (ext.310). Be sure to include your article number.

If you have any questions regarding your article, please contact me. PLEASE ALWAYS INCLUDE YOUR ARTICLE NO. (209PNR) WITH ALL CORRESPONDENCE.

This e-proof is to be used only for the purpose of returning corrections to the publisher.

Sincerely,

Production Editor, SYN DPS Ephrata E-mail: jrnlprodsyn@cadmus.com Tel: 717-721-2622 Fax: 717-738-9478 or 717-738-9479



#### \*\*\*IMMEDIATE RESPONSE REQUIRED\*\*\*

Please follow these instructions to avoid delay of publication.

#### READ PROOFS CAREFULLY

- This will be your only chance to review these proofs.
- Please note that the volume and page numbers shown on the proofs are for position only.

ANSWER ALL QUERIES ON PROOFS (Queries for you to answer are attached as the last page of your proof.)

 Mark all corrections directly on the proofs. Note that excessive author alterations may ultimately result in delay of publication and extra costs may be charged to you.

#### CHECK FIGURES AND TABLES CAREFULLY

- Check size, numbering, and orientation of figures.
- All images in the PDF are downsampled (reduced to lower resolution and file size) to facilitate Internet delivery. These images will appear at higher resolution and sharpness in the printed article.
- Review figure legends to ensure that they are complete.
- Check all tables. Review layout, title, and footnotes.

#### COMPLETE REPRINT ORDER FORM

• Fill out the attached reprint order form. It is important to return the form <u>even if you are not ordering reprints</u>. You may, if you wish, pay for the reprints with a credit card. Reprints will be mailed only after your article appears in print. This is the most opportune time to order reprints. If you wait until after your article comes off press, the reprints will be considerably more expensive.

#### □ ADDITIONAL COPIES

• If you wish to purchase additional copies of the journal in which your article appears, please contact Kim Lloyd at (201) 748-8839, fax (201) 748-8888, or E-mail at klloyd@wiley.com

#### RETURN

#### 

CTA (If you have not already signed one)

#### RETURN WITHIN 48 HOURS OF RECEIPT VIA FAX TO 717-738-9478 or 717-738-9479

QUESTIONS?

#### **Production Editor, SYN**

Phone: 717-721-2622 E-mail: jrnlprodjemt@cadmus.com Refer to journal acronym (SYN) and article production number

### Softproofing for advanced Adobe Acrobat Users - NOTES tool

NOTE: ACROBAT READER FROM THE INTERNET DOES NOT CONTAIN THE NOTES TOOL USED IN THIS PROCEDURE.

Acrobat annotation tools can be very useful for indicating changes to the PDF proof of your article. By using Acrobat annotation tools, a full digital pathway can be maintained for your page proofs.

The NOTES annotation tool can be used with either Adobe Acrobat 6.0 or Adobe Acrobat 7.0. Other annotation tools are also available in Acrobat 6.0, but this instruction sheet will concentrate on how to use the NOTES tool. Acrobat Reader, the free Internet download software from Adobe, DOES NOT contain the NOTES tool. In order to softproof using the NOTES tool you must have the full software suite Adobe Acrobat Exchange 6.0 or Adobe Acrobat 7.0 installed on your computer.

#### Steps for Softproofing using Adobe Acrobat NOTES tool:

1. Open the PDF page proof of your article using either Adobe Acrobat Exchange 6.0 or Adobe Acrobat 7.0. Proof your article on-screen or print a copy for markup of changes.

2. Go to Edit/Preferences/Commenting (in Acrobat 6.0) or Edit/Preferences/Commenting (in Acrobat 7.0) check "Always use login name for author name" option. Also, set the font size at 9 or 10 point.

3. When you have decided on the corrections to your article, select the NOTES tool from the Acrobat toolbox (Acrobat 6.0) and click to display note text to be changed, or Comments/Add Note (in Acrobat 7.0).

4. Enter your corrections into the NOTES text box window. Be sure to clearly indicate where the correction is to be placed and what text it will effect. If necessary to avoid confusion, you can use your TEXT SELECTION tool to copy the text to be corrected and paste it into the NOTES text box window. At this point, you can type the corrections directly into the NOTES text box window. **DO NOT correct the text by typing directly on the PDF page.** 

5. Go through your entire article using the NOTES tool as described in Step 4.

6. When you have completed the corrections to your article, go to Document/Export Comments (in Acrobat 6.0) or Comments/Export Comments (in Acrobat 7.0). Save your NOTES file to a place on your harddrive where you can easily locate it. **Name your NOTES file with the article number assigned to your article in the original softproofing e-mail message.** 

#### 7. When closing your article PDF be sure NOT to save changes to original file.

8. To make changes to a NOTES file you have exported, simply re-open the original PDF proof file, go to Document/Import Comments and import the NOTES file you saved. Make changes and reexport NOTES file keeping the same file name.

9. When complete, attach your NOTES file to a reply e-mail message. Be sure to include your name, the date, and the title of the journal your article will be printed in.



#### E-MAIL: reprints@wiley.com PREPUBLICATION REPRINT ORDER FORM

**Please complete this form even if you are not ordering reprints.** This form **MUST** be returned with your corrected proofs and original manuscript. Your reprints will be shipped approximately 4 weeks after publication. Reprints ordered after printing will be substantially more expensive.

JOURNAL SYNAPSE				VOLUME	IS	SSUE	
TITLE OF							
MANUSCRIPT							
MS. NO	NO. OF PAGES	AUTHOR(S	5)				
No. of Pages	100 Reprints	200 Reprints	300 Rep	orints	400 Reprints	500 1	Reprints
	\$	\$	\$		\$		\$
1-4	336	501	694	ļ.	890	1	052
5-8	469	703	987	7	1251	1	477
9-12	594	923	123	4	1565	1	850
13-16	714	1156	152	7	1901	2	273
17-20	794	1340	177	5	2212	2	648
21-24	911	1529	203	2031		3	037
25-28	1004	1707	226	2267 2828		3	388
29-32	1108	1894	251	2515 3135		3	755
33-36	1219	2092	277	3	3456	4	143
37-40	1329	2290	303	3	3776	4	528
REPRINTS DEPARTME	NT AT (212) 850-8789 FO	R A PRICE QUOTE.					
Please send me		reprints of the above	ve article at		\$		_
Please add appropriate State and Local Tax for United States orders only.		(Tax Exempt No		)	\$		_
		Please add 5% Post	age and Handlin	g	\$		_
		TOTAL AMOUNT	Г OF ORDER**		\$		_
**International orders m Please check one: If credit card order, charg	ust be paid in currency and Check enclosed ge to: America	an Express	Bill me Visa		Credit Card MasterCard		
Credit Card No		Signature				Exp. Date	
BILL TO: Name			SHIP TO: Name	(Please, r	no P.O. Box numbers)		
Institution			Institution				
Address			Address				
Durahasa Ordan Na			Phone		Fe		
Purchase Order No.			Phone		Fax		
			E-mail				

# **COPYRIGHT TRANSFER AGREEMENT**



Date:	_ Contributor name:	
Contributor address:		
Manuscript number (Editorial o	ffice only):	
Re: Manuscript entitled		
		 (the "Contribution")
for publication in		 (the "Journal")
published by		 ("Wiley-Blackwell").

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable Wiley-Blackwell to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement signed and returned as directed in the Journal's instructions for authors as soon as possible. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.** 

#### A. COPYRIGHT

1. The Contributor assigns to Wiley-Blackwell, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to publish, republish, transmit, sell, distribute and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

**2.** Reproduction, posting, transmission or other distribution or use of the final Contribution in whole or in part in any medium by the Contributor as permitted by this Agreement requires a citation to the Journal and an appropriate credit to Wiley-Blackwell as Publisher, and/or the Society if applicable, suitable in form and content as follows: (Title of Article, Author, Journal Title and Volume/Issue, Copyright © [year], copyright owner as specified in the Journal). Links to the final article on Wiley-Blackwell's website are encouraged where appropriate.

#### **B. RETAINED RIGHTS**

Notwithstanding the above, the Contributor or, if applicable, the Contributor's Employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution.

#### C. PERMITTED USES BY CONTRIBUTOR

**1. Submitted Version**. Wiley-Blackwell licenses back the following rights to the Contributor in the version of the Contribution as originally submitted for publication:

**a.** After publication of the final article, the right to self-archive on the Contributor's personal website or in the Contributor's institution's/employer's institutional repository or archive. This right extends to both intranets and the Internet. The Contributor may not update the submission version or replace it with the published Contribution. The version posted must contain a legend as follows: This is the pre-peer reviewed version of the following article: FULL CITE, which has been published in final form at [Link to final article].

**b.** The right to transmit, print and share copies with colleagues.

**2.** Accepted Version. Re-use of the accepted and peer-reviewed (but not final) version of the Contribution shall be by separate agreement with Wiley-Blackwell. Wiley-Blackwell has agreements with certain funding agencies governing reuse of this version. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/funderstatement. NIH grantees should check the box at the bottom of this document.

**3. Final Published Version.** Wiley-Blackwell hereby licenses back to the Contributor the following rights with respect to the final published version of the Contribution:

**a.** Copies for colleagues. The personal right of the Contributor only to send or transmit individual copies of the final published version in any format to colleagues upon their specific request provided no fee is charged, and further-provided that there is no systematic distribution of the Contribution, e.g. posting on a listserve, website or automated delivery.

**b.** Re-use in other publications. The right to re-use the final Contribution or parts thereof for any publication authored or edited by the Contributor (excluding journal articles) where such re-used material constitutes less than half of the total material in such publication. In such case, any modifications should be accurately noted.

**c.** Teaching duties. The right to include the Contribution in teaching or training duties at the Contributor's institution/place of employment including in course packs, e-reserves, presentation at professional conferences, in-house training, or distance learning. The Contribution may not be used in seminars outside of normal teaching obligations (e.g. commercial seminars). Electronic posting of the final published version in connection with teaching/training at the Contributor's institution/place of employment is permitted subject to the implementation of reasonable access control mechanisms, such as user name and password. Posting the final published version on the open Internet is not permitted.

**d.** Oral presentations. The right to make oral presentations based on the Contribution.

# 4. Article Abstracts, Figures, Tables, Data Sets, Artwork and Selected Text (up to 250 words).

**a.** Contributors may re-use unmodified abstracts for any non-commercial purpose. For on-line uses of the abstracts, Wiley-Blackwell encourages but does not require linking back to the final published versions.

**b.** Contributors may re-use figures, tables, data sets, artwork, and selected text up to 250 words from their Contributions, provided the following conditions are met:

- (i) Full and accurate credit must be given to the Contribution.
- (ii) Modifications to the figures, tables and data must be noted. Otherwise, no changes may be made.
- (iii) The reuse may not be made for direct commercial purposes, or for financial consideration to the Contributor.
- (iv) Nothing herein shall permit dual publication in violation of journal ethical practices.

#### D. CONTRIBUTIONS OWNED BY EMPLOYER

1. If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/employer which must sign this Agreement (in addition to the Contributor's signature) in the space provided below. In such case, the company/employer hereby assigns to Wiley-Blackwell, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in paragraph A above.

2. In addition to the rights specified as retained in paragraph B above and the rights granted back to the Contributor pursuant to paragraph C above, Wiley-Blackwell hereby grants back, without charge, to such company/employer, its subsidiaries and divisions, the right to make copies of and distribute the final published Contribution internally in print format or electronically on the Company's internal network. Copies so used may not be resold or distributed externally. However the company/employer may include information and text from the Contribution as part of an information package included with software or other products offered for sale or license or included in patent applications. Posting of the final published Contribution by the institution on a public access website may only be done with Wiley-Blackwell's written permission, and payment of any applicable fee(s). Also, upon payment of Wiley-Blackwell's reprint fee, the institution may distribute print copies of the published Contribution externally.

#### E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Govern-

ment purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end)

#### F. COPYRIGHT NOTICE

The Contributor and the company/employer agree that any and all copies of the final published version of the Contribution or any part thereof distributed or posted by them in print or electronic format as permitted herein will include the notice of copyright as stipulated in the Journal and a full citation to the Journal as published by Wiley-Blackwell.

#### G. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. If the Contribution was prepared jointly, the Contributor agrees to inform the co-Contributors of the terms of this Agreement and to obtain their signature to this Agreement or their written permission to sign on their behalf. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in Wiley-Blackwell's permissions form or in the Journal's Instructions for Contributor, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury.

CHECK ONE BOX:		
Contributor-owned work		
ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY	Contributor's signature	Date
	Type or print name and title	
	<u>., here here are are are</u>	
	Co-contributor's signature	Date
	Type or print name and title	
Company/Institution-owned work		
(made-for-hire in the course of employment)	Company or Institution (Employer-for-Hire)	Date
	Authorized signature of Employer	Date
U.S. Government work	Note to U.S. Government Employees A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work," and is in the public domain in the United States. In such case, the employee may cross out Paragraph A.1 but must sign (in the Contributor's signature line) and return this Agreement. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.	
U.K. Government work (Crown Copyright)	Note to U.K. Government Employees The rights in a Contribution prepared by an employee of a U.K. government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. U.K. government authors should submit a signed declaration form together with this Agreement. The form can be obtained via http://www.opsi.gov.uk/advice/crown-copyright/copyright-guidance/ publication-of-articles-written-by-ministers-and-civil-servants.htm	
Other Government work	Note to Non-U.S., Non-U.K. Government Employees If your status as a government employee legally prevents you from signing this Agreement, please contact the editorial office.	
NIH Grantees	Note to NIH Grantees Pursuant to NIH mandate, Wiley-Blackwell will post the accepted version of Contributions authored by NIH grant-holders to PubMed Central upon acceptance. This accepted version will be made publicly available 12 months after publication. For further information, see www.wiley.com/go/nihmandate.	



# **SYNAPSE**

#### 111 RIVER STREET, 8<sup>TH</sup> FLOOR, HOBOKEN, NJ 07030

Telephone Number:	Facsimile Number:
To:	Production Editor, SYN
Fax:	717-738-9478 or 717-738-9479
From:	
Date:	·
Re:	
Pages (including cover sheet)	

Message:

SYNAPSE 00:000-000 (2009)

# Nicotine Withdrawal Produces a Decrease in Extracellular Levels of Dopamine in the Nucleus Accumbens that is Lower in Adolescent Versus Adult Male Rats

LUIS A. NATIVIDAD, HUGO A. TEJEDA, OSCAR V. TORRES, AND LAURA E. O'DELL\* Department of Psychology, The University of Texas at El Paso, El Paso, Texas 79968

*KEY WORDS* development; adolescence; nicotinic; in vivo microdialysis; highperformance liquid chromatography (HPLC)-EC; extracellular; DOPAC; HVA; 5-HIAA; rat; abstinence; GABA; bicuculline; ventral tegmental area

ABSTRACT The behavioral effects of nicotine withdrawal are lower in adolescent versus adult rats. However, the neurochemical mechanisms that mediate these developmental differences are unknown. Previous studies have shown that extracellular levels of dopamine in the nucleus accumbens (NAcc) are reduced in adult rats experiencing withdrawal. This study compared dopamine levels in the NAcc of male adolescent and adult rats experiencing nicotine withdrawal. Animals were prepared with subcutaneous pumps that delivered an equivalent nicotine dose in these age groups. Following 13 days of nicotine exposure, rats were implanted unilaterally with microdialysis probes into the NAcc and ipsilateral ventral tegmental area (VTA). The next day, dialysate levels were collected following systemic administration of the nicotinic-receptor antagonist mecanylamine to precipitate withdrawal. Mecanylamine produced an average % decrease in NAcc dopamine that was lower in adolescents (20%) versus adults (44%). Similar developmental differences were observed with the dopaminergic (DOPAC and HVA) but not serotonergic (5-HIAA) metabolites. A follow-up study compared NAcc dopamine in adolescent and adult rats receiving intra-VTA administration of bicuculline, which reduces  $\gamma$ -aminobutyric acid (GABA) inhibition of dopamine transmission. The results revealed that blockade of GABA<sub>A</sub> receptors in the VTA produced a twofold increase in NAcc dopamine of adults but not adolescents. These results provide a potential mechanism involving dopamine that mediates developmental differences in nicotine withdrawal. Specifically, they suggest that GABA systems are underdeveloped during adolescence and this reduced inhibition of dopamine neurons in the VTA may lead to reduced decreases in NAcc dopamine of young animals experiencing withdrawal. Synapse 00:000-000, 2009. © 2009 Wiley-Liss, Inc.

#### **INTRODUCTION**

Much research suggests that tobacco dependence in adults is mediated, in large part, by avoiding the negative consequences of nicotine withdrawal (Benowitz, 2008; Buchhalter et al., 2008; Carmody et al., 2007). However, the contribution of withdrawal to tobacco use during adolescence has not been well established. Preclinical animal studies have suggested that both the physical and negative affective properties of nicotine withdrawal are lower in adolescent relative to adult rats. For example, work in our laboratory has

\*Correspondence to: Laura E. O'Dell, Ph.D., The University of Texas at El Paso, Department of Psychology, 500 West University, El Paso, TX 79968, USA. E-mail: lodell@utep.edu

Received 27 February 2009; Accepted 29 May 2009

DOI 10.1002/syn.20713

Published online in Wiley InterScience (www.interscience.wiley.com).

© 2009 WILEY-LISS, INC.

ID: manokaranp Date: 26/6/09 Time: 16:46 Path: J:/Production/SYN#/Vol00000/090084/3B2/C2SYN#090084 NOTE TO AUTHORS: This will be your only chance to review this proof. Once an article appears online, even as an EarlyView article, no additional corrections will be made.

Contract grant sponsor: National Institute on Drug Abuse; Contract grant number: R01-DA021274; Contract grant sponsor: UTEP BBRC-RCMI; Contract grant number: 5G12RR008124; Contract grant sponsor: NIH Ruth L. Kirschstein Fellowship program; Contract grant number: F31DA021133; Contract grant sponsor: The American Psychological Association, Diversity Program in Neuroscience; Contract grant number: T32-MH018882-20.

#### L.A. NATIVIDAD ET AL.

demonstrated that adolescent rats display fewer physical signs of nicotine withdrawal and reduced place aversion to environmental cues previously associated with nicotine withdrawal relative adult rats (O'Dell et al., 2004, 2006, 2007). Work in other laboratories has further established that the behavioral effects of nicotine withdrawal are lower in adolescent rats (Shram et al., 2008) and mice (Kota et al., 2007, 2008) relative to their adult counterparts. Collectively, these studies suggest that adolescence is a period of development characterized by reduced sensitivity to nicotine withdrawal. Also, these findings suggest that the underlying neural mechanisms that mediate withdrawal are different across various stages of development. However, the neural mechanisms that mediate developmental differences in nicotine withdrawal are presently unclear.

The reinforcing effects of nicotine are mediated in large part by enhanced dopamine neurotransmission in the mesolimbic pathway (Corrigall, 1991; Mansvelder and McGehee, 2002; Watkins et al., 2000). This pathway originates in the ventral tegmental area (VTA) and projects to various forebrain structures, including the nucleus accumbens (NAcc), which plays a critical role in mediating the rewarding effects of drugs of abuse.

Recent studies have demonstrated that the neurochemical effects of nicotine withdrawal are opposite to the increases in extracellular levels of NAcc dopamine following nicotine administration. Studies investigating the neurochemical effects of nicotine withdrawal have used mecamylamine, a pharmacological agent that blocks nicotinic acetylcholine receptors and precipitates withdrawal in animals previously exposed to nicotine for at least 5-7 days. For example, studies examining the neurochemical effects of nicotine withdrawal have demonstrated that adult rats showing physical signs of nicotine withdrawal display a 20-35% decrease in extracellular levels of dopamine in the NAcc relative to baseline levels (Carboni et al., 2000; Gaddnas et al., 2002; Hildebrand et al., 1998, 1999; Rada et al., 2001). The latter studies also found that nicotine withdrawal produces a decrease in NAcc levels of the dopamine metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA).

The hypothesis that the neural mechanisms of withdrawal involve decreased NAcc dopamine levels is consistent with studies showing reduced levels of NAcc dopamine during withdrawal from alcohol, opiates, and cocaine (Pothos et al., 1991; Rada et al., 2004; Weiss et al., 1992). However, to our knowledge, changes in NAcc dopamine levels have not been compared in adolescent and adult rats experiencing nicotine withdrawal. Thus, the goal of this study was to compare developmental differences to changes in extracellular levels of dopamine and the dopamine metabolites, DOPAC and HVA, in the NAcc of adoles-

Synapse

cent and adult rats experiencing nicotine withdrawal. To assess the role of serotonergic systems in mediating developmental differences in nicotine withdrawal, this study also included a comparison of changes in one of the major serotonin metabolites, 5-hydroxyindoleacetic acid (5-HIAA).

Much work has shown that dopamine release in the NAcc is inhibited by γ-aminobutyric acid (GABA) neurotransmission in the dopamine cell body region of the VTA. The inhibition of dopamine in the VTA occurs via a population of GABA interneurons that form synapses onto VTA dopamine neurons that project to the NAcc (Johnson and North, 1992; Kalivas, 1993; Mansvelder and McGehee, 2002; Mansvelder et al., 2002). Microdialysis studies demonstrate that intra-VTA infusions of a GABA<sub>A</sub> receptor antagonist increase NAcc dopamine levels (Ikemoto et al., 1997; Westerink et al., 1996), whereas intra-VTA infusions of a GABA<sub>A</sub> agonist decrease NAcc dopamine levels (Westerink et al., 1996). Although the inhibition of dopamine release via GABA systems has been well established, to our knowledge no one has compared the ability of GABA systems to inhibit dopamine release in the NAcc of adolescent and adult rats. Thus, this study also examined developmental differences to neurochemical changes in NAcc dopamine produced by intra-VTA administration of a GABA<sub>A</sub> antagonist.

#### MATERIALS AND METHODS Animals

Male Wistar adolescent and adult rats (n = 7-8 per group) were used. Adolescents were between postnatal day (PND) 28-30 and adults were between PND 60–75 at the time of the pump implantation surgery. All rats were handled for 5 days prior to the start of experimentation and were given free access to food and water throughout the study. Rats were housed in groups of two to three per cage in a humidity- and temperature-controlled (20-22°C) vivarium using a 12-/12-h light/dark cycle with lights on at 8:00 AM. The home cage consisted of a rectangular  $Plexiglas^{(R)}$  hanging cage (41.5 cm long  $\times$  17 cm wide imes 21 cm high) with pine bedding. The food and water were located above the animals' living space on a wire platform encased within a filtered top cover. Testing procedures were conducted during the light phase of the rats' light/dark cycle. The rats were bred in the Psychology Department from a stock of outbred Wistar rats from Harlan, Inc (Indianapolis, IN). Rats were bred onsite to minimize stress in adolescents that might have occurred if they had been shipped and tested close in time. All procedures were approved by the University of Texas at El Paso Animal Care and Use Committee and followed the guide-

 $\mathbf{2}$ 

#### NEUROCHEMICAL EFFECTS OF WITHDRAWAL IN ADOLESCENCE

lines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

#### Drugs

The drugs used in this experiment were (-) nicotine-hydrogen tartrate and mecamylamine hydrochloride purchased from Sigma Aldrich Inc. (St. Louis, MO), and bicuculline methochloride purchased from Tocris Biosciences Inc (Ellisville, MO). Mecamylamine was dissolved in 0.9% sterile saline and injected via the intraperitoneal (IP) route of administration in a volume of 1 ml/kg. Bicuculline was dissolved in artificial cerebral spinal fluid (ACSF) and administered via reverse dialysis through the microdialysis probe that was surgically implanted into the VTA.

#### Surgical preparation of osmotic pumps

Rats were anesthetized with an isofluorane/oxygen mixture (1–3% isofluorane) prior to surgical preparation of 14-day Alzet osmotic pumps purchased from Durect Corporation (model 2ML2; 1.0 µl/h; Cupertino, CA) that were implanted subcutaneously on the back of the animal parallel to the spine. Pumps were filled with nicotine (4.7 mg/kg/day for adolescents or 3.2 mg/kg/day for adults; expressed as base). The concentration of nicotine in the pump was adjusted according to the weight of the rat at the time of the surgery. The nicotine concentrations were based on previous studies demonstrating that the infusion rate of nicotine was 1.5 times lower in adolescent versus adult rats after 17 days of exposure to the same nicotine dose as used in this study (see Trauth et al., 2000). After surgery, the surgical incision was closed with 9-mm stainless steel wound clips and treated with a topical antibiotic ointment.

# Stereotaxic implantation of microdialysis probes

Thirteen days after the pump surgery, rats were implanted unilaterally with two probes into the NAcc and the ipsilateral VTA. Rats were implanted between PND 40-42 for adolescents and PND 72-87 for adults. The probes were purchased from CMA-Microdialysis (model CMA 11; Solna, Sweden) with an active membrane length of 2 mm in the NAcc and 1 mm in the VTA. The probes were perfused for at least 1 h prior to implantation at a rate of 0.5 µl/min with ACSF composed of 145 mM NaCl, 2.8 mM KCl, 1.2 mM CaCl<sub>2</sub>, 1.2 mM MgCl<sub>2</sub>, 5.4 mM d-glucose, and 0.25 mM ascorbic acid and adjusted to a pH of 7.2-7.4. The probes were stereotaxically implanted into the brain regions using the following coordinates for the NAcc from bregma [adolescent placements-anterior-posterior (AP) =  $\pm 2.2$ , medial-lateral (ML) =  $\pm 0.8$ , dorsal-ventral (DV) = -7.1; and adult placements- AP = +1.7, ML = ±1.4, DV = -8.1] and the ipsilateral VTA [adolescent placement- AP = -4.0, ML = ±0.6, DV = -7.4; and adult placements- AP = -4.8, ML = ±0.8, DV = -8.5]. Adolescent placements were derived from Philpot et al. (2001) and Pistis et al. (2004) and adult placements were derived from O'Dell and Parsons (2004). The hemisphere that was implanted with the probe was randomized across treatment groups to control for possible hemispheric differences across age groups.

Following surgery, adolescent and adult animals were transferred to similar-sized test cages that consisted of a square  $Plexiglas^{(R)}$  cage (24 cm long  $\times$ 24 cm wide  $\times$  31 cm high) with pine bedding. Food and water were available throughout dialysis testing. When comparing adolescent and adult rats, some researchers are careful to adjust for the size of the cage since this factor has been shown to influence exploratory behaviors such as sniffing, rearing, and locomotor activity. This may be particularly important for studies assessing developmental differences in affective measures such as anxiety-like behavior that are influenced by exploratory behavior. However, previous work in our laboratory using different sized chambers has consistently revealed that adolescent and adult rats tested in chambers of different sizes and shapes (round versus square) display similar basal and somatic signs of withdrawal (O'Dell et al., 2004 and 2006). Furthermore, our measures of the physical signs of withdrawal do not include exploratory behaviors and thus are not likely influenced by cage size.

#### **Microdialysis testing**

The next day after probe implantation, the perfusate flow rate was increased to 1.0 µl/min for 1 h to allow equilibration of the probes. Samples were then collected in 10-min intervals for 1 h to establish a baseline period, and then following a systemic injection of saline and two doses of mecamylamine in increasing order (1.5 and 3.0 mg/kg, expressed as salt; IP). The doses of mecamylamine were chosen based on previous studies demonstrating that they produce a place aversion to environmental cues previously associated with withdrawal in nicotine-dependent rats (O'Dell et al., 2007). In addition, reports from other laboratories have demonstrated that similar doses of mecamylamine produce decreases in extracellular levels of NAcc dopamine ( $\sim 20-35\%$  from baseline) in nicotine-dependent adult rats experiencing withdrawal (Carboni et al., 2000; Gaadnas et al., 2002; Rada et al., 2001).

The last series of dialysate samples were collected during a 1-h perfusion of bicuculline-methochloride into the VTA probe (100  $\mu$ M). This manipulation was

Synapse

3

#### L.A. NATIVIDAD ET AL.

done to compare developmental differences in the ability of GABA<sub>A</sub> receptor blockade to increase NAcc dopamine levels. All dialysate samples collected from the NAcc probe were diluted with 10  $\mu$ l of a perchloric-acid solution (0.05 N) in order to preserve our samples and prevent degradation of dopamine and the metabolites. After sample collection, the samples were immediately frozen on dry ice and then stored in a  $-70^\circ\mathrm{C}$  freezer until they were analyzed within the next 1–3 weeks.

4

# Assessment of physical signs of nicotine withdrawal

Rats were monitored for somatic signs of nicotine withdrawal for three separate 10-min observation periods after administration of saline and then again after administration of the two doses of mecamylamine during microdialysis testing. The observed signs included blinks, writhes, body shakes, teeth chatters, gasps, and ptosis. These measures of withdrawal have been used as a reliable index of the physical signs of withdrawal in nicotine-dependent adolescent and adult rats receiving a systemic injection of mecamylamine (Malin et al., 1994; O'Dell et al., 2004, 2006; Shram et al., 2008). Animals were continuously observed for 10 min, during which time the number of times the animals exhibited any of the above signs were recorded. Multiple successive counts of any sign required a distinct pause between episodes. If present continuously, ptosis was only counted once. The total number of somatic signs was defined as the sum of individual occurrences of the aforementioned withdrawal signs during the entire 10-min observation period.

#### Neurochemical analysis of dopamine, DOPAC, HVA, and 5-HIAA

Dopamine and the metabolites were quantified from a 10-µl sample injected into a HPLC system equipped with an ESA HR-80  $80 \times 4.6$  mm column (3-µm BetaBasic packing material, C-18 stationary phase, Chelmsford, MA) and eluted using a mobile phase composed of a 75 mM NaH<sub>2</sub>PO<sub>4</sub> (monohydrate, monobasic) buffer (pH 3.75) with 10% acetonitrile, 0.025 mM sodium-EDTA, 0.4% (v/v) triethylamine and 1.7 mM 1-octanesulfonic acid sodium salt delivered at 1 ml/min by an ESA model 580 syringe pump (Chelmsford, MA). Quantification was achieved via an ESA Coulochem II detector equipped with a coulometric sensor containing dual glassy carbon working electrodes (Chelmsford, MA) set at +350 mV for the metabolites and -150 mV for dopamine. The extracellular levels of dopamine and the metabolites were estimated using external calibration curves with standards containing known concentrations of these neurochemicals.

Synapse

Histology

At the end of the experiment, all rats were deeply sedated with pentobarbital (100 mg/kg, salt; IP) for systemic perfusion using 0.85% saline and then a 4% paraformaldehyde solution. Following the perfusion, the brains were extracted and stored in formalin solution until they were sectioned. Verification of the probe placements was verified during sectioning using the Paxinos and Watson (1998) atlas. The probe placements were focused in the NAcc core region for both adolescents and adults, as determined during sectioning of the brain tissue. The VTA placements were all confined in this region. As a final elimination criterion, each animals' baseline values had to fall within a range that was less than two standard deviations from the group mean in order to be included in the final analysis. On the basis of these criteria, n =three adolescents and n = two adults were excluded from the study.

#### **Statistical analyses**

Total overt signs of nicotine withdrawal were analyzed using repeated-measures ANOVA with age (adolescent and adult) as a between-subjects factor and drug treatment (saline and mecamylamine) as a within-subject factor. Repeated-measures ANOVA were first conducted to examine whether there were basal differences in dopamine, DOPAC, HVA, and 5-HIAA levels in adolescent and adult rats. The data revealed that there were no differences in basal levels of dopamine or any of the metabolites. Our subsequent analyses were conducted on values that were converted to % change from baseline [i.e., (dialysate value/average baseline value)  $\times$  100%] in order to more clearly illustrate group differences. The data were then analyzed using repeated-measures ANOVA with age (adolescent and adult) as a between-subjects factor and time (10-min intervals) as a within-subject factor. Changes in neurotransmitter levels during the intra-VTA bicuculline infusion were analyzed separately using repeated-measures ANOVA with age (adolescent and adult) as a between-subjects factor and time (10-min intervals during the three samples prior to and the six samples following the intra-VTA bicuculline infusion) as a within-subject factor. Significant interaction effects were further analyzed using Fisher's least significant difference (LSD) tests and a modified Bonferroni correction factor for alpha inflation.

#### **RESULTS** Physical signs of withdrawal

Figure 1 illustrates the physical signs of nicotine F1 withdrawal in adolescent and adult rats. Overall, the results revealed that mecamylamine precipitated



Fig. 1. Data reflect total somatic signs of withdrawal (±SEM) exhibited in a 10-min observation period during baseline and following mecamylamine administration in adolescent and adult rats (n = 7-8 per group). Asterisks (\*) denote significant differences from baseline values (Ps < 0.05), and daggers (†) denote significant differences between age groups (Ps < 0.05).

physical signs of withdrawal relative to baseline, and this effect was larger in nicotine-dependent adult versus adolescent rats. Baseline withdrawal signs were not different between adolescents ( $5.8 \pm 0.7$ ) and adults ( $6.4 \pm 0.9$ ) [F(1, 12) = 0.4; P = ns]. Our analyses revealed a significant interaction between age and drug treatment [F(2, 22) = 4.3; P < 0.05]. Subsequent posthoc analyses revealed that both age groups displayed an increase in the physical signs of withdrawal relative to baseline levels following mecamylamine administration, and this effect was larger in adult versus adolescent rats (Ps < 0.05).

#### NAcc dopamine during nicotine withdrawal

F2

Figure 2 illustrates % change from baseline levels of NAcc dopamine (±SEM) in adolescent and adult rats experiencing nicotine withdrawal. Overall, the results revealed that mecamylamine produced a decrease in extracellular levels of NAcc dopamine that was larger in nicotine-dependent adult versus adolescent rats. There were no age differences in baseline dopamine levels across adolescent (2.8  $\pm$ 0.2 nM) versus adult (2.9  $\pm$  0.1 nM) rats [F(1, 14) = 0.3; P = ns]. Our analyses revealed a significant interaction between age and time [F(23, 322) = 2.0;P < 0.05], with both age groups displaying a decrease in NAcc dopamine following mecamylamine administration that was larger in adult versus adolescent rats. Specifically, adult rats displayed a larger decrease in dopamine (average decrease of 44.1  $\pm$ 5.5% from baseline levels) versus adolescent rats (average decrease of 20.1  $\pm$  5.3% from baseline levels). Subsequent posthoc analyses revealed that the



Fig. 2. Data reflect % change from baseline levels of NAcc dopamine ( $\pm$ SEM) plotted across 10-min sample collections during baseline and following administration of saline and then two doses of mecamylamine to precipitate withdrawal in adolescent and adult rats (n = 7-8 per group). There were no group differences in baseline dopamine levels in adolescent ( $2.8 \pm 0.2$  nM) versus adult ( $2.9 \pm 0.1$  nM) rats. The arrows indicate the onset of drug administration. Asterisks (\*) denote significant differences from baseline levels (Ps < 0.05) and daggers (†) denote significant differences between age groups (Ps < 0.05).

adult rats displayed a significant decrease in NAcc dopamine relative to baseline at all time points following mecamylamine except for the sample that was collected before administration of the highest dose of mecamylamine (Ps < 0.05). In contrast, adolescents only displayed a significant decrease from baseline during the 2nd–5th, 9th and 11th–12th time points after mecamylamine administration (Ps < 0.05). Posthoc analyses examining age differences revealed that adults displayed larger decreases in NAcc dopamine levels relative to adolescents at the 1st, 2nd, 7th, and 12th time points after mecamylamine administration (Ps < 0.05).

#### NAcc DOPAC during nicotine withdrawal

Figure 3 illustrates % change from baseline levels of NAcc DOPAC (±SEM) in adolescent and adult rats experiencing nicotine withdrawal. Overall, the results revealed that mecamylamine produced a decrease in extracellular levels of NAcc DOPAC that was larger in nicotine-dependent adult versus adolescent rats. There were no age differences in baseline DOPAC levels in adolescent (487.8  $\pm$  52.1 nM) versus adult  $(517.9 \pm 47.9 \text{ nM})$  rats [F(1, 12) = 0.2; P = ns]. Our analyses revealed a significant interaction between age and time [F(23, 276) = 1.6; P < 0.05], with adults displaying a decrease in NAcc DOPAC levels following mecamylamine administration that was larger than the adolescent rats. Specifically, adult rats displayed a decrease in DOPAC levels (average decrease of 20  $\pm$  14.3% from baseline levels) that was not altered in adolescent rats. Post-hoc analyses revealed that adult rats displayed a significant

Synapse

F3

5

NEUROCHEMICAL EFFECTS OF WITHDRAWAL IN ADOLESCENCE



Fig. 3. Data reflect % change from baseline levels of NAcc DOPAC (±SEM) plotted across 10-min sample collections during baseline and following administration of saline and then two doses of mecamylamine to precipitate withdrawal in adolescent and adult 7-8 per group). There were no group differences in baserats (n =line DOPAC levels in adolescent (487.8  $\pm$  52.1 nM) versus adult  $(517.9 \pm 47.9 \text{ nM})$  rats. The arrows indicate the onset of drug administration. Asterisks (\*) denote significant differences from baseline levels (Ps < 0.05) and daggers (†) denote significant differences between age groups (Ps < 0.05).

decrease relative to baseline levels during the final time point after mecamylamine administration (P <0.05). Also, the post-hoc analyses examining age differences revealed that adults displayed larger decreases in NAcc DOPAC levels relative to adolescents during the 1st, 5th, and 12th time points after mecamylamine administration (Ps < 0.05). It should be noted that adults displayed an increase in NAcc DOPAC levels during the 3rd, 5th, and 6th time points after saline administration (Ps < 0.05). However, adolescents did not display this effect following saline administration.

#### NAcc HVA during nicotine withdrawal

Figure 4 illustrates % change from baseline levels F4of NAcc HVA (±SEM) in adolescent and adult rats experiencing nicotine withdrawal. Overall, the results revealed that mecamylamine produced a decrease in extracellular levels of NAcc HVA that was larger in nicotine-dependent adult versus adolescent rats. There were no age differences in baseline HVA levels in adolescent (395.7  $\pm$  41.3 nM) versus adult (328.7  $\pm$ 38.6 nM) rats [F(1, 12) = 1.4; P = ns]. Our analyses revealed a significant interaction between age and time [F(23, 276) = 1.9; P < 0.05] with adults, but not adolescents displaying a time-dependent decrease in NAcc HVA levels. Specifically, adult rats displayed a decrease in HVA levels (average decrease of 21  $\pm$ 8.4% from baseline levels) that was not observed in adolescents. Post-hoc analyses revealed that adults displayed a significant decrease in NAcc HVA levels relative to baseline during the final three time points after administration of the highest mecamylamine

Synapse

200 Mecamvlamine Mecamylamine 1.5 mg/kg (IP) Saline (IP) 3.0 mg/kg (IP) NAcc HVA (% Baseline) 150 100 Baseline 50 O Adolescent Adult 0 ò 20 40 60 80 100 120 140 160 180 200 220 Time (10-minute intervals)

Fig. 4. Data reflect % change from baseline levels of NAcc HVA (±SEM) plotted across 10-min sample collections during baseline and following administration of saline and then two doses of mecamylamine to precipitate withdrawal in adolescent and adult rats = 7-8 per group). There were no group differences in baseline HVA levels in adolescent (395.7  $\pm$  41.3 nM) versus adult (328.7  $\pm$ 38.6 nM) rats. The arrows indicate the onset of drug administration. Asterisks (\*) denote significant differences from baseline levels  $(Ps\ <\ 0.05)$  and the dagger (†) denotes a significant difference between age groups (P < 0.05).

dose (Ps < 0.05). Also, post-hoc analyses examining age differences produced by mecamylamine administration revealed that adults displayed a larger decrease in HVA levels relative to adolescents during the last time point after administration of the highest mecamylamine dose (P < 0.05). It should be noted that adults displayed an increase in NAcc HVA levels during the 5th and 6th time points after saline administration (Ps < 0.05). However, adolescent rats did not display this effect following saline administration.

#### NAcc 5-HIAA during nicotine withdrawal

F5

F6

Figure 5 illustrates % change from baseline levels of NAcc 5-HIAA (±SEM) in adolescent and adult rats experiencing nicotine withdrawal. The results revealed that mecamylamine did not produce changes in extracellular levels of NAcc 5-HIAA in nicotinedependent adolescent or adult rats.

#### NAcc dopamine during intra-VTA administration of bicuculline

Figure 6 illustrates % change from baseline levels of NAcc dopamine during the three samples prior to and the six samples following intra-VTA administration of bicuculline in adolescent and adult rats. Overall, the results revealed that blockade of GABAA receptors in the VTA produced an increase in extracellular levels of NAcc dopamine of adult but not adolescent rats. There were no age differences in dopamine levels during the three samples prior to bicuculline administration across adolescent  $(2.2 \pm 0.2 \text{ nM})$ 

#### L.A. NATIVIDAD ET AL.



#### NEUROCHEMICAL EFFECTS OF WITHDRAWAL IN ADOLESCENCE

Fig. 5. Data reflect % change from baseline levels of NAcc HVA ( $\pm$ SEM) plotted across 10-min sample collections during baseline and following administration of saline and then two doses of meca-mylamine to precipitate withdrawal in adolescent and adult rats (n = 7-8 per group). There were no group differences in baseline 5-HIAA levels in adolescent (169.2  $\pm$  29.0 nM) versus adult (225.3  $\pm$  49.8 nM) rats. The arrows indicate onset of drug administration.

versus adult (1.6  $\pm$  0.2 nM) rats [F(1, 14) = 3.8; P = ns]. Our analyses revealed a significant interaction between age and time [F(8, 88) = 17.9; P < 0.05],with adult rats displaying increases in NAcc dopamine that were higher versus adolescents. Specifically, adults displayed a twofold increase in dopamine following bicuculline infusion (i.e., from 56.0  $\pm$  7.5% to  $125.9 \pm 10.7$ ), whereas adolescents only showed a slight increase (i.e., from 77.4  $\pm$  5.5% to 87.9  $\pm$  7.3%) in these measures. Post-hoc analyses revealed that during the final three time points, adults displayed significant increases in NAcc dopamine relative to the three samples prior to bicuculline (Ps < 0.05). In contrast, adolescents only displayed a significant increase in NAcc dopamine during the final time point relative to the three samples prior to bicuculline (P < 0.05). Also, post-hoc analyses examining age differences revealed that adults displayed significantly higher NAcc dopamine relative to adolescents during the final three time points after bicuculline (Ps < 0.05).

#### DISCUSSION

The major finding of this report is that the physical signs of nicotine withdrawal and decreases in extracellular levels of dopamine in the NAcc were lower in adolescent versus adult rats. The pattern of developmental differences in dopamine was also consistent with the metabolites of this neurotransmitter, as decreases in extracellular levels of DOPAC and HVA were also lower in the NAcc of adolescent versus adult rats. The present report also demonstrated that intra-VTA administration of a GABA<sub>A</sub> antagonist produced an increase in NAcc dopamine that was lower in adolescent versus adult rats. Thus, one possible mechanism to explain reduced changes in NAcc dopamine that compare the text of the set of the



Fig. 6. Data reflect % change from baseline levels of NAcc dopamine plotted across 10-min sample collections during the three samples prior to and the six samples following intra-VTA bicuculline administration in adolescent and adult rats (n = 7-8 per group). Asterisks (\*) denote significant differences relative to the three samples collected prior to bicuculline administration (Ps < 0.05), and daggers (†) denote significant differences between age groups (Ps < 0.05).

mine during withdrawal in adolescent rats is that inhibition of dopamine in the VTA is underdeveloped such that adolescents display less of a decrease in NAcc dopamine during withdrawal.

The present finding that the physical signs of nicotine withdrawal are lower in adolescent versus adult rats is consistent with previous behavioral studies. For example, adolescent rats display fewer physical signs of withdrawal relative to adults across a range of nicotine doses to produce dependence, and across a range of mecamylamine doses to precipitate withdrawal (O'Dell et al., 2006). Furthermore, work in our laboratory and others have demonstrated that the negative affective properties of nicotine withdrawal are also lower in adolescent versus adult rats (O'Dell et al., 2007) and mice (Kota et al., 2007, 2008). On the basis of these previous studies and the present findings, we suggest that adolescence is a period of development characterized by reduced sensitivity to the behavioral and neurochemical effects of nicotine withdrawal.

Our neurochemical results extend previous behavioral studies by providing a potential mechanism for reduced sensitivity to nicotine withdrawal during adolescence. This mechanism involves reduced dopamine transmission in the NAcc, an effect that has been well established in adult rats experiencing withdrawal from nicotine (Carboni et al., 2000; Gaddnas et al., 2002; Hildebrand et al., 1998, 1999; Rada et al., 2001) as well as other drugs of abuse (Pothos et al., 1991; Rada et al., 2004; Weiss et al., 1992). The latter studies regarding nicotine withdrawal have reported a 20–35% decrease in extracel-

Synapse

7

#### L.A. NATIVIDAD ET AL.

lular levels of NAcc dopamine during nicotine withdrawal, and the magnitude of this effect is consistent with the 44% decrease in NAcc dopamine observed in this study. The major contribution of this report to the literature; however, is that adolescent rats only displayed a 20% decrease in extracellular levels of NAcc dopamine during nicotine withdrawal.

Consistent with the developmental differences in the dopamine data, adolescent rats also displayed decreases in the dopaminergic metabolites DOPAC and HVA that were lower relative to adults. The metabolite data are useful for several reasons. First, they provide a supplementary (albeit, indirect) verification of the changes we observed with dopamine neurotransmission since the metabolites generally produced similar patterns of developmental differences during withdrawal. Thus, our metabolite data provided a verification of the developmental differences observed with dopamine using a measure that produced a large neurochemical signal. Second, the metabolite data allowed us to detect differences that were not observed with dopamine, such as the increases in DOPAC and HVA levels observed in adult rats receiving saline. The saline-induced increases in the metabolites might reflect acute stress in the adult animal produced by a systemic injection. This effect has also been observed in nicotine-dependent adult animals following intra-VTA administration of saline (Hildebrand et al., 1999). Third, the metabolite data suggest that our developmental differences are specific to dopaminergic systems, since neither age group displayed changes in 5-HIAA levels during withdrawal. This is consistent with previous studies showing that 5-HIAA levels are not altered in adult rats experiencing nicotine withdrawal (Gaddnas et al., 2002; Hildebrand et al., 1998).

In this study, mecamylamine was used as a pharmacological tool to compare developmental differences in the neurochemical effects of withdrawal. Thus, our comparisons focused on adolescent and adult rats that were exposed to nicotine and then given mecamylamine to precipitate withdrawal. It may be argued that our observed changes in dopamine and its metabolites reflect age-dependent differences in response to mecamylamine given in combination with chronic nicotine treatment versus mecamylamine given alone. However, our previous place conditioning studies revealed that adolescents chronically exposed to nicotine still demonstrate less sensitivity to mecamylamine-precipitated withdrawal versus adults, even in separate groups of adolescents that received a twofold higher dose of mecamylamine or 7 additional days of nicotine exposure (O'Dell et al., 2007). Furthermore, in the absence of mecamylamine, the removal of a nicotine pump still produces less spontaneous signs of withdrawal in adolescent versus adult rats (Shram et al., 2008) and mice (Kota et al., 2007).

Synapse

It is also unlikely that developmental differences observed in this study can be attributed to the effects of mecamylamine alone, since several reports have shown that this drug has little behavioral or neurochemical effects in the absence of nicotine. For example, administration of the mecamylamine doses used in this study do not alter the physical signs of withdrawal or produce place aversion in naïve adolescent and adult rats (O'Dell et al., 2007; Shram et al., 2008) or mice (Kota et al., 2007). Also, separate laboratories have shown that mecamylamine alone does not alter extracellular levels of dopamine in the NAcc of naïve adult rats (Carboni et al., 2000; Gaddnas et al., 2002; Hildebrand and Svensson, 2000; Rada et al., 2001). Taken together, these studies suggest that our results are not influenced by developmental differences in response to mecamylamine alone. However, this potential limitation in the interpretation of the present findings might be addressed in future empirical studies comparing developmental differences in nicotinic receptor function.

It should be noted that adolescents display faster weight gain and metabolic breakdown of nicotine than adults. Thus, it may also be suggested that the lack of withdrawal in adolescents is due to lower levels of nicotine on the day of microdialysis testing relative to adults. However, this potential confound was likely avoided because we implanted the adolescent rats with a pump containing a 1.5-fold higher dose of nicotine as compared with adults. This adjustment factor was based on a study showing that after 17 days of nicotine pump exposure, the infusion rates of nicotine were 1.5 times lower in adolescent (3-4 mg/kg/day) versus adult rats (5 mg/kg/day; Trauth et al., 2000). Thus, one might expect that adolescents receiving 1.5 times more nicotine than adults would display equivalent nicotine levels as adults on the test day following 14 days of nicotine exposure. Moreover, we have demonstrated that place aversion produced by nicotine withdrawal is still lower in a group of adolescents that were tested after 21 days of nicotine exposure during which time they received a new pump containing an adjusted nicotine dose 14 days after the initial pump implantation (O'Dell et al., 2007). Also, Kota et al., (2007) demonstrated that adolescent mice given repeated systemic injections of nicotine that were adjusted for weight still display less physical and affective signs of withdrawal as compared to adults. Taken together, these studies suggest that the developmental differences observed in this study are not likely due to developmental differences in nicotine dosing or tolerance; however, future studies might directly assess this possibility at the time point that was used in this study.

This study also explored the hypothesis that developmental differences in NAcc dopamine are mediated via GABAergic inhibition of dopamine cell bodies in

8

#### NEUROCHEMICAL EFFECTS OF WITHDRAWAL IN ADOLESCENCE

the VTA. Our rationale for examining GABAergic systems was based on the finding that blockade of  $GABA_A$  receptors in the VTA produces a 40-80% increase in NAcc dopamine levels, whereas stimulation of these receptors induces a 60% decrease in this measure (see Ikemoto et al., 1997; Westerink et al., 1996). Indeed, theese findings are consistent with previous reports, as intra-VTA infusions of bicuculline produced a twofold increase in dopamine levels in the NAcc of adult rats. However, our results also demonstrated that blockade of GABAA receptors in the VTA did not alter dopamine levels in the NAcc of adolescent rats. On the basis of this finding, we suggest that the inability of bicuculline to increase NAcc dopamine levels in adolescent rats is due to underdeveloped GABAergic inhibition of VTA dopamine neurons that release dopamine in the NAcc. Our hypothesis is based on previous studies showing that during adolescence, inhibitory postsynaptic potentials in GABA neurons are slower, less frequent, and weaker in response to GABA agonists relative to neurons from mature animals (see Cohen et al., 2000). Also, GABA-mediated inhibition of postsynaptic GABA<sub>B</sub> receptors is not functional early in life and GABA currents in neonatal rat neurons are insensitive to benzodiazepine activation of GABA<sub>A</sub> receptors (Cherubini et al., 1991). Thus, it is possible that adolescent rats display reduced decreases in dopamine activity during nicotine withdrawal because of a lack of inhibition in the VTA cell body region. We recognize that our interpretation of these data may be limited on the basis of pharmacological studies, and future studies will need to more directly assess our hypothesis by comparing extracellular levels of GABA in the VTA of adolescent and adult rats experiencing nicotine withdrawal.

To our knowledge, this is the first study to demonstrate that the neurochemical effects of nicotine withdrawal are lower in adolescent versus adult rats. Recent studies have shown that the neurochemical effects of nicotine administration are enhanced in adolescent versus adult rats. For example, a recent study reported that systemic administration of nicotine produces a larger increase in extracellular levels of dopamine and DOPAC in the NAcc of adolescent versus adult rats (Shearman et al., 2008). In addition, Azam et al. (2007) showed that nicotine-stimulated release of <sup>3</sup>[H]dopamine is elevated in synaptosomes collected from the NAcc of adolescent versus adult rats. These reports showing that the neurochemical effects of nicotine are enhanced during adolescence are also consistent with several behavioral studies showing that the rewarding effects of nicotine are enhanced during adolescence (Chen et al., 2007; Kota et al., 2007, 2008; Levin et al., 2003, 2007; Shram et al., 2006; Torres et al., 2008; Vastola et al., 2002). Taken together, these studies suggest that the positive rewarding effects of nicotine are enhanced, whereas the negative effects of nicotine withdrawal are reduced during adolescence. These opposite behavioral phenomena appear to be related to changes in dopamine systems, as the neurochemical effects of nicotine are enhanced whereas decreases in dopamine during withdrawal are reduced during adolescence. Thus, adolescent vulnerability to nicotine addiction may be associated with increased sensitivity to the rewarding effects of nicotine and reduced sensitivity to the negative aversive effects of nicotine withdrawal.

9

In conclusion, the present findings may have clinical relevance for treating adolescent tobacco abuse. Specifically, the finding that adolescents display reduced withdrawal suggests that treatments focusing on alleviating nicotine withdrawal may be less effective in treating adolescent tobacco users. As an example, treatments that enhance dopamine neurotransmission (i.e., bupropion) may be less effective in adolescent smokers that experience less of a decrease in dopamine levels during withdrawal. There is clinical evidence to support our suggestion that treatments focusing on alleviating withdrawal are less effective in adolescent tobacco abusers. For example, it has been demonstrated that long-term abstinence rates do not appear to be closely associated with nicotine replacement therapies in adolescent smokers (Hanson et al., 2003: Hurt et al., 2000; Moolchan et al., 2005). Furthermore, there is evidence to suggest that nicotine replacement does not prevent the expression of nicotine withdrawal symptoms in adolescent smokers (Killen et al., 2001). Moreover, a recent study directly comparing adolescent smokers to nonsmokers found that young smokers only exhibit mild symptoms during withdrawal (anger and craving) that do not appear to be associated with selfreports of dependence or biological markers of cigarette use (Smith et al., 2008a). Another report from this laboratory found that withdrawal symptoms on the quit day were not related to relapse behavior in adolescent smokers (Smith et al., 2008b). These studies suggest that abstinence from chronic tobacco abuse only produces mild withdrawal symptoms that are not related to continued use or relapse behavior during adolescence. Thus, treatments focusing on alleviating withdrawal may be less effective in young tobacco abusers. Future studies are needed to examine whether treatments that target nicotine withdrawal via enhanced dopamine neurotransmission are equally effective in adolescent and adult smokers.

#### ACKNOWLEDGMENTS

The authors thank Drs. Eddie Castañeda, Kristin Gosselink, Donald Moss, and Christina Sobin for their helpful input during the preparation of this manuscript. The authors also thank Arturo Orona and Francisco Roman for their technical assistance.

Synapse

10

#### L.A. NATIVIDAD ET AL.

#### REFERENCES

- Azam L, Chen Y, Leslie FM, 2007, Developmental regulation of nico-
- Azam L, Chen Y, Leshe FM. 2007. Developmental regulation of nico-tinic acetylcholine receptors within midbrain dopamine neurons. Neuroscience 144:1347–1360.
   Buchhalter AR, Fant RV, Henningfield JE. 2008. Novel pharmaco-logical approaches for treating tobacco dependence and with-drawal: Current status. Drugs 68:1067–1088.
- Benowitz NL. 2008. Neurobiology of nicotine addiction: Implications for smoking cessation treatment. Am J Med 121:3-10.
- Berrendero F, Kieffer BL, Maldonado R. 2002. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J Neurosci 22:10935-10940.
- Carboni E, Bortone L, Giua C, Di Chiara G. 2000. Dissociation of physical abstinence signs from changes in extracellular dopamine in the nucleus accumbens and in the prefrontal cortex of nicotine dependent rats. Drug Alcohol Depend 58:93-102.
- dependent rats. Drug Alcohol Depend 58:93-102.
  Carmody TP, Vieten C, Astin JA. 2007. Negative affect, emotional acceptance, and smoking cessation. J Psychoactive Drugs 39:499-508.
  Chen H, Matta SG, Sharp BM. 2007. Acquisition of nicotine self-administration in adolescent rats given prolonged access to the drug. Neuropsychopharmacology 32:700-709.
  Cherubini E, Gaiarsa JL, Ben-Ari Y. 1991. GABA: An excitatory transmitter in early postnatal life. Trends Neurosci 14:515-519.
  Cohen AS, Lin DD, Coulter DA 2000. Protracted nostnatal development.
- Cohen AS, Lin DD, Coulter DA. 2000. Protracted postnatal development of inhibitory synaptic transmission in rat hippocampal area CA1 neurons. J Neurophysiol 84:2465–2476.
- Corrigall WA. 1991. Understanding brain mechanisms in nicotine reinforcement. Br J Addict 86:507-510.
- Gaddnas H, Piepponen TP, Ahtee L. 2002. Mecamylamine decreases accumbal dopamine output in mice treated chronically with nicotine. Neurosci Lett 330:219-222
- Hanson K, Allen S, Jensen S, Hatsukami D. 2003. Treatment of adolescent smokers with the nicotine patch. Nicotine Tobacco Res 5:515 - 526
- Hildebrand BE, Nomikos GG, Hertel P, Schilstrom B, Svensson TH. 1998. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res 779.214-225
- Hildebrand BE, Panagis G, Svensson TH, Nomikos GG. 1999. Behavioral and biochemical manifestations of mecamylamine-precipitated nicotine withdrawal in the rat: Role of nicotinic receptors in the ventral tegmental area. Neuropsychopharmacology 21:560–574.
- Hildebrand BE, Svensson TH. 2000. Intraaccumbal mecamylamine infusion does not affect dopamine output in the nucleus accumbens of chronically nicotine-treated rats. J Neural Trans 107:861–872. Hurt RD, Croghan GA, Beede SD, Wolter TD, Croghan IT, Patten CA
- 2000. Nicotine patch therapy in 101 adolescent smokers: Efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels. Arch Pediatrics Adolescent Med 154:31-37
- Ikemoto S, Kohl RR, McBride WJ. 1997. GABA-A receptor blockade in the anterior ventral tegmental area increases extracellular levels of dopamine in the nucleus accumbens of rats. J Neurochem 69:137-143.
- Johnson SW, North RA. 1992. Two types of neurons in the rat ventral tegmental area and their synaptic inputs. J Physiol (Lond) 450:455-468.
- Kalivas PW. 1993. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Rev 18:75-113.
- Killen JD, Ammerman S, Rojas N, Varady J, Haydel F, Robinson TN. 2001. Do adolescent smokers experience withdrawal effects when deprived of nicotine? Exp Clin Psychopharmacol 9:176–182.
- Kota D, Martin BR, Robinson SE, Damaj MI. 2007. Nicotine de-pendence and reward differ between adolescent and adult male mice. J Pharmacol Exp Therapeutics 322:399-407
- Kota D, Martin BR, Damaj MI. 2008. Age-dependent differences in nicotine reward and withdrawal in female mice. Psychopharmacology 198:201-210.
- Levin ED, Rezvani A, Montoya R, Rose J, Swartrzwelder H. 2003. Adolescent-onset nicotine self-administration modeled in female
- rats. Psychopharmacology 169:141–149. Levin ED, Lawrence SS, Petro A, Horton K, Rezvani AH, Seidler FJ, Slotkin TA. 2007. Adolescent vs. adult-onset nicotine self-
- administration in male rats: Duration of effect and differential nicotinic receptor correlates. Neurotoxicol Teratol 29:458–465. Malin DH, Lake JR, Carter VA, Cunningham JS, Hebert KM, Con-rad DL, Wilson OB. 1994. The nicotinic antagonist mecanylamine precipitates nicotine abstinence syndrome in the rat. Psychophar-
- macology (Berlin) 115:180–184. Mansvelder HD, McGehee DS. 2002. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 53:606–617.

Synapse

Mansvelder HD, Keath JR, McGehee DS. 2002. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33:905-919.

- Moolchan ET, Robinson ML, Ernst M, Cadet JL, Pickworth WB, Heishman SJ, Schroeder JR. 2005. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. Pediatrics 115:407-414.
- O'Dell LE, Parsons LH. 2004. Serotonin-1B receptors in the ventral tegmental area modulate cocaine-induced increases in nucleus accumbens dopamine levels. J Pharmacol Exp Therapeutics 311:711-719.
- O'Dell LE, Bruijnzeel AW, Ghozland S, Markou A, Koob GF. 2004. Nicotine withdrawal in adolescent and adult rats. Ann NY Acad Sci 1021:167–174.
- O'Dell LE, Bruijnzeel AW, Smith RT, Parsons LH, Merves ML, Gold-berger BA, Koob GF, Markou A. 2006. Diminished nicotine withdrawal in adolescent rats: Implications for vulnerability to addiction. Psychopharmacology 186:612–619.
- O'Dell LE, Torres OV, Natividad LA, Tejeda HA. 2007. Adolescent nicotine exposure produces less affective measures of withdrawal relative to adult nicotine exposure in male rats. Neurotoxicol Teratol 29:17-22.
- Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates, 4th ed. New York: Academic Press
- Philpot RM, McQuown S, Kirstein CL. 2001. Stereotaxic localization of the developing nucleus accumbens septi. Develop Brain Res 130:149-153.
- Pistis M, Perra S, Pillolla G, Melis M, Muntoni AL, Gessa GL. 2004. Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry 56:86–94. Pothos E, Rada P, Mark GP, Hoebel BG. 1991. Dopamine microdial-
- prise in the nucleus accumbens during acute and chronic mor-phine, naloxone-precipitated withdrawal and clonidine treatment. Brain Res 566:348-50.
- Rada P, Jensen K, Hoebel BG. 2001. Effects of nicotine and mecamylamine-induced withdrawal on extracellular dopamine and acetylcholine in the rat nucleus accumbens. Psychopharmacology 157:105-110.
- Rada P, Johnson DF, Lewis MJ, Hoebel BG. 2004. In alcohol-treated rats, naloxone decreases extracellular dopamine and increases ac-etylcholine in the nucleus accumbens: Evidence of opioid withdrawal, Pharmacol Biochem Behav 79:599-605.
- Salas R, Pieri F, De Biasi M. 2004. Decreased signs of nicotine withdrawal in mice null for the beta4 nicotinic acetylcholine receptor subunit. J Neurosci 24:10035–10039
- Shearman E, Fallon S, Sershen H, Lajtha A. 2008. Nicotine-induced monoamine neurotransmitter changes in the brain of young rats. Brain Res Bull 76:626-639.
- Shram MJ, Funk D, Li Z, Le AD. 2006. Periadolescent and adult rats respond differently in tests measuring the rewarding and aversive effects of nicotine. Psychopharmacology 186:201-208
- Shram MJ, Siu EC, Li Z, Tyndale RF, Le AD. 2008. Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats. Psychopharmacology 198:181–190.
- Smith AE, Cavallo DA, Dahl T, Wu R, George TP, Krishnan-Sarin S. 2008a. Effects of acute tobacco abstinence in adolescent smokers as compared with nonsmokers. J Adolescent Health 43:46-54.
- Smith AE, Cavallo DA, McFetridge A, Liss T, Krishnan-Sarin S. 2008b. Preliminary examination of tobacco withdrawal in adolescent smokers during smoking cessation treatment. Nicotine
- Tobacco Res 10:1253–1259. Torres OV, Tejeda HA, Natividad LA, O'Dell LE. 2008. Enhanced vulnerability to the rewarding effects of nicotine during the adolescent period of development. Pharmacol Biochem Behav 90:658-663.
- Trauth JA, Seidler FJ, Slotkin TA. 2000. An animal model of adolescent nicotine exposure: Effects on gene expression and macromolecular constituents in rat brain regions. Brain Res 867:29-39.
- Vastola BJ, Douglas LA, Varlinskaya EI, Spear LP. 2002. Nicotine-induced conditioned place preference in adolescent and adult rats. Physiol Behav 77:107–114.
- Watkins SS, Koob GF, Markou A. 2000. Neural mechanisms underlying nicotine addiction: Acute positive reinforcement and withdrawal. Nicotine Tobacco Res 2:19-37.
- Weiss F, Markou A, Lorang MT, Koob GF. 1992. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res 593:314-318
- Westerink BH, Kwint HF, deVries JB. 1996. The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J Neurosci 16:2605–2611.

AQ1: Please confirm that all author names OK and are set with first name first, surname last.

